Approval of aducanumab for Alzheimer’s disease

EAN guidance on managing patients with dementia

Medical management issues in dementia: recommendations

The benefits of GWAS in understanding Alzheimer’s disease

Therapeutic development in Alzheimer’s disease and the lack of funding

Cross neurodegenerative disease genetic analysis: similarities and differences

Dementia, stress and the molecular age of the brain

Identifying new therapeutic targets for neurodegenerative diseases

The future of Alzheimer’s disease: aducanumab

Dementia and stress: the challenges

Hopeful developments for Alzheimer’s Disease

Defining Alzheimer’s disease: clinical or biological

CT1812: exciting preliminary results

A673T mutation lowers Aβ oligomer binding affinity: Alzheimer’s disease protective mechanism

Therapeutics designed to mimic protective mutations for Alzheimer’s disease

The role of phosphorylated tau in clinical trials